1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. Middle East and Africa RNAi Therapeutics Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. Middle East and Africa RNAi Therapeutics Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1 RNAi Therapeutics in Cancer Therapy
5.2 Market Opportunities
- 5.2.1 Imaging Modalities for RNAi Therapeutics for RNAi Therapeutics
5.3 Future Trends
- 5.3.1 Rising Research & Development (R&D) activity
5.4 Impact of Drivers and Restraints
6. Middle East and Africa RNAi Therapeutics Market Regional Analysis
6.1 Middle East and Africa RNAi Therapeutics Market Overview
6.2 Middle East and Africa RNAi Therapeutics Market Revenue 2017-2027 (US$ Million)
6.3 Middle East and Africa RNAi Therapeutics Market Forecast Analysis
7. Middle East and Africa RNAi Therapeutics Market Analysis – by Molecule Type
7.1 Small Interfering RNAs
- 7.1.1 Overview
- 7.1.2 Small Interfering RNAs: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
7.2 MicroRNA
- 7.2.1 Overview
- 7.2.2 MicroRNA: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2031 (US$ Million)
8. Middle East and Africa RNAi Therapeutics Market Analysis – by Application
8.1 Genetic Disorders
- 8.1.1 Overview
- 8.1.2 Genetic Disorders: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.2 Oncology
- 8.2.1 Overview
- 8.2.2 Oncology: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.3 Neurodegenerative Disorders
- 8.3.1 Overview
- 8.3.2 Neurodegenerative Disorders: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.4 Cardiovascular
- 8.4.1 Overview
- 8.4.2 Cardiovascular: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.5 Respiratory Disorders
- 8.5.1 Overview
- 8.5.2 Respiratory Disorders: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.6 Infectious Diseases
- 8.6.1 Overview
- 8.6.2 Infectious Diseases: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
8.7 Renal Diseases
- 8.7.1 Overview
- 8.7.2 Renal Diseases: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9. Middle East and Africa RNAi Therapeutics Market Analysis – by Route of Administration
9.1 Intradermal Injections
- 9.1.1 Overview
- 9.1.2 Renal Diseases: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.2 Pulmonary Delivery
- 9.2.1 Overview
- 9.2.2 Renal Diseases: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.3 Intravenous Injections
- 9.3.1 Overview
- 9.3.2 Renal Diseases: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
9.4 Intraperitoneal Injections
- 9.4.1 Overview
- 9.4.2 Renal Diseases: Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
10. Middle East and Africa RNAi Therapeutics Market – Middle East and Africa Analysis
10.1 Middle East and Africa
- 10.1.1 Middle East and Africa RNAi Therapeutics Market Breakdown, by Key
Country, 2020 and 2027 (%)
- 10.1.1.1 Middle East and Africa RNAi Therapeutics Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 South Africa:
Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.1.1 South Africa: Middle East and Africa RNAi Therapeutics Market Breakdown, by Molecule Type
- 10.1.1.1.2 South Africa: Middle East and Africa RNAi Therapeutics Market Breakdown, by Application
- 10.1.1.1.3 South Africa: Middle East and Africa RNAi Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.2 Saudi Arabia:
Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.2.1 Saudi Arabia: Middle East and Africa RNAi Therapeutics Market Breakdown, by Molecule Type
- 10.1.1.2.2 Saudi Arabia: Middle East and Africa RNAi Therapeutics Market Breakdown, by Application
- 10.1.1.2.3 Saudi Arabia: Middle East and Africa RNAi Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.3 UAE:
Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.3.1 UAE: Middle East and Africa RNAi Therapeutics Market Breakdown, by Molecule Type
- 10.1.1.3.2 UAE: Middle East and Africa RNAi Therapeutics Market Breakdown, by Application
- 10.1.1.3.3 UAE: Middle East and Africa RNAi Therapeutics Market Breakdown, by Route of Administration
- 10.1.1.4 Rest of Middle East and Africa:
Middle East and Africa RNAi Therapeutics Market – Revenue and Forecast to 2027 (US$ Million)
- 10.1.1.4.1 Rest of Middle East and Africa: Middle East and Africa RNAi Therapeutics Market Breakdown, by Molecule Type
- 10.1.1.4.2 Rest of Middle East and Africa: Middle East and Africa RNAi Therapeutics Market Breakdown, by Application
- 10.1.1.4.3 Rest of Middle East and Africa: Middle East and Africa RNAi Therapeutics Market Breakdown, by Route of Administration
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. Middle East and Africa RNAi Therapeutics Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Benitec Biopharma
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 GlaxoSmithKline plc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Olix Pharmaceuticals, Inc.
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Alnylam Pharmaceuticals, Inc.
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Arrowhead Pharmaceuticals, Inc.
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
14. Appendix
14.1 About Business Market Insights